Growing community of inventors

Avondale, PA, United States of America

Bhavnish Parikh

Average Co-Inventor Count = 3.81

ph-index = 9

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 163

Bhavnish ParikhKrishnaswamy Yeleswaram (16 patents)Bhavnish ParikhWilliam Valentine Williams (6 patents)Bhavnish ParikhBhavesh Shah (6 patents)Bhavnish ParikhYong Ni (6 patents)Bhavnish ParikhSusan Erickson-Viitanen (6 patents)Bhavnish ParikhDilip P Modi (4 patents)Bhavnish ParikhTrupti Sheth (4 patents)Bhavnish ParikhBhavnish Parikh (16 patents)Krishnaswamy YeleswaramKrishnaswamy Yeleswaram (20 patents)William Valentine WilliamsWilliam Valentine Williams (28 patents)Bhavesh ShahBhavesh Shah (10 patents)Yong NiYong Ni (6 patents)Susan Erickson-ViitanenSusan Erickson-Viitanen (6 patents)Dilip P ModiDilip P Modi (4 patents)Trupti ShethTrupti Sheth (4 patents)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Incyte Corporation (15 from 665 patents)

2. Incyte Holdings Corporation (10 from 147 patents)

3. Incyte Holdings Comoration (1 from 1 patent)


16 patents:

1. 12226419 - Topical formulation for a JAK inhibitor

2. 12151026 - Sustained release dosage forms for a JAK1 inhibitor

3. 11896717 - Sustained-release dosage forms of ruxolitinib

4. 11590136 - Topical formulation for a JAK inhibitor

5. 11576864 - Sustained-release dosage forms of ruxolitinib

6. 11576865 - Sustained-release dosage forms of ruxolitinib

7. 11571425 - Topical formulation for a JAK inhibitor

8. 11337927 - Sustained-release dosage forms of ruxolitinib

9. 11219624 - Topical formulation for a JAK inhibitor

10. 11045421 - Sustained release dosage forms for a JAK1 inhibitor

11. 10874616 - Sustained-release dosage forms of ruxolitinib

12. 10869870 - Topical formulation for a JAK inhibitor

13. 10758543 - Topical formulation for a JAK inhibitor

14. 10561616 - Sustained release dosage forms for a JAK1 inhibitor

15. 10166191 - Sustained-release dosage forms of ruxolitinib

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/8/2025
Loading…